Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7900+0.1200 (+2.57%)
At close: 04:00PM EDT
4.7500 -0.04 (-0.84%)
After hours: 04:07PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

    In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023. Previously announced programs for lead asset batoclimab continue at full speed. Two asset anti-FcRn franchise offers multiple potential development and commercial synergies, with composition of matter patent protection expected for IMVT-1402 through at lea

  • Insider Monkey

    These 10 Stocks are Getting Crushed on Monday

    In this article, we will take a look at the 10 stocks getting crushed on Monday. If you want to see some more companies on the list, go directly to These 5 Stocks are Getting Crushed on Monday. U.S. stocks inched up before the opening bell today. However, the gains couldn’t continue for long. All […]

  • GlobeNewswire

    Immunovant to Present at Roivant Investor Day on September 28th

    NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022. Roivant Investor Day presentation details: Date: Wednesday, September 28th, 2022 Time: 11:15 am Eastern Time Webcast: The presentation will be

Advertisement
Advertisement